Stakeholders interviewed in Pakistan expressed broad support for introducing a novel tuberculosis (TB) vaccine targeted to adolescents and adults. Support was driven primarily by recognition of Pakistan’s high TB burden and the limitations of current prevention tools. However, stakeholders emphasized that endorsement would be conditional on clear, high-quality evidence demonstrating the vaccine’s safety, effectiveness, and practical feasibility for delivery in the local context.
This exploratory qualitative study used semi-structured in-depth interviews with purposively selected key stakeholders involved in TB control, immunization, clinical care, and health policy in Pakistan. Participants represented national and provincial TB programs, the Expanded Programme on Immunization (EPI), clinical settings, and academia. Interviews were conducted in English or Urdu, audio-recorded, transcribed verbatim, and analyzed using reflexive thematic analysis following the Braun and Clarke framework. The coding approach was hybrid, combining deductive and inductive methods. Ten stakeholders participated; one interview also served as a pilot test of the interview guide.
Respondents highlighted the potential public health impact of a new TB vaccine in reducing disease burden among adolescents and adults, groups not well covered by the existing Bacillus Calmette–Guérin (BCG) vaccine programs focused on infants. Stakeholders perceived vaccination as a potentially transformative prevention strategy that could complement case-finding and treatment services, particularly given ongoing transmission and limitations of current control measures.
Stakeholders identified a range of social and cultural barriers that could undermine vaccine acceptance. Low perceived personal risk of TB in many communities, pervasive misinformation about vaccines, and stigma associated with TB were named repeatedly. Sociocultural influences, including community norms and potentially influential family or religious leaders, were noted as factors that could either hinder or facilitate acceptance depending on engagement. Limited public awareness about adult-targeted vaccination programs was also seen as a challenge to uptake.
Participants emphasized that proactive community engagement and communication strategies would be essential. Engaging trusted healthcare providers to deliver messages and serve as vaccination points was seen as critical for credibility. Clear, context-specific information addressing safety and effectiveness, and efforts to counter misinformation and stigma, were identified as priorities to build public trust and demand. Stakeholders recommended using existing, trusted structures rather than creating parallel systems.
Health system readiness concerns were prominent. Stakeholders reported workforce shortages that could constrain outreach and clinic-based vaccination activities. Cold chain limitations, particularly for delivery outside established infant immunization sites, were flagged as operational challenges. Financing constraints at national and provincial levels were cited as further barriers to scaling up a new vaccination program for adolescents and adults without dedicated resources and planning.
There was consensus among participants on priority populations for initial vaccine rollout. Household contacts of people with TB were consistently identified as the top priority group, followed by adolescents and people living with HIV. These groups were perceived as having higher risk of infection or progression and thus likely to yield measurable public health benefits if targeted early in a phased program.
Stakeholders broadly favored a phased implementation strategy rather than immediate universal rollout. A phased approach would allow early targeting of high-priority groups, assessment of programmatic feasibility, monitoring of safety and effectiveness in real-world settings, and gradual integration into existing health services such as school-based platforms or adult immunization channels. Gradual integration into routine services was preferred to creating standalone delivery systems.
The study obtained ethical approval from Aga Khan University and Emory University institutional review boards (IRB references provided in the source). All participants provided informed consent and transcripts were de-identified; data are available from the authors upon reasonable request. The study declared funding from the National Institutes of Health (1K01AI166093-01A1). The authors reported no competing interests.
Conclusion
Stakeholders in Pakistan support the introduction of a novel TB vaccine for adolescents and adults conditional on strong evidence of safety and effectiveness, and on assurance of programmatic feasibility. Overcoming sociocultural barriers, implementing targeted community engagement, addressing misinformation and stigma, and strengthening health system components such as workforce, cold chain, and financing will be key to successful rollout. Early stakeholder engagement and phased implementation with integration into existing services were recommended to maximize public health impact in Pakistan.